Beliefs and preferences regarding biological treatments for severe asthma by A. Bikov et al.
Bikov et al. World Allergy Organization Journal (2020) 13:100441
http://doi.org/10.1016/j.waojou.2020.100441Open Access
Beliefs and preferences regarding biological
treatments for severe asthma
Andras Bikova,b, Ipek Kivilcim Oguzülgenc, Ilaria Baiardinid, Marco Contolie, Alexander Emelyanovf,
Omar Fassiog, Juan Carlos Ivancevichh, Igor Kaidashevi, Krzysztof Kowalj, Marina Labork,l,
Lies Lahoussem, Stefan Mihaicutan, Silviya Novakovao, Alicia Padilla Galop, Alexander Simidchievq,
Angelica Tiotiur,s, Ignacio J. Ansoteguit, Jonathan A. Bernsteinu, Louis Philippe Bouletv,
Giorgio Walter Canonicaw,x, Lawrence Dubuskey, Nelson Rosarioz, Pierachille Santusaa and
Fulvio Braidoab,ac*, on Behalf of Interasma Scientific Network (INES)1abM
King
*Co
Inter
1 Th
are
FullABSTRACT
Background: Severe asthma is a serious condition with a significant burden on patients’
morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and
interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison
studies, the choice of which medication to use varies. We aimed to explore the beliefs and
practices in the use of biological therapies in severe asthma, hypothesizing that differences will
occur depending on the prescribers’ specialty and experience.
Methods: We conducted an online survey composed of 35 questions in English. The survey was
circulated via the INterasma Scientific Network (INESNET) platform as well as through social
media. Responses from allergists and pulmonologists, both those with experience of prescribing
omalizumab with (OMA/IL5) and without (OMA) experience with anti-IL5 drugs, were compared.
Results: Two hundred eighty-five (285) valid questionnaires from 37 countries were analyzed.
Seventy-on percent (71%) of respondents prescribed biologics instead of oral glucocorticoids and
believed that their side effects are inferior to those of Prednisone 5 mg daily. Agreement with ATS/
ERS guidelines for identifying severe asthma patients was less than 50%. Specifically, significant
differences were found comparing responses between allergists and pulmonologists (Chi-square
test, p < 0.05) and between OMA/IL5 and OMA groups (p < 0.05).
Conclusions: Uncertainties and inconsistencies regarding the use of biological medications have
been shown. The accuracy of prescribers to correctly identify asthma severity, according to
guidelines criteria, is quite poor. Although a substantial majority of prescribers believe that bio-
logical drugs are safer than low dose long-term treatment with oral steroids, and that they must be
used instead of oral steroids, every effort should be made to further increase awareness. Efficacy
as disease modifiers, biomarkers for selecting responsive patients, timing for outcomes evaluation,
and checks need to be addressed by further research. Practices and beliefs regarding the use of
asthma biologics differ between the prescriber’s specialty and experience; however, the latter
seems more significant in determining beliefs and behavior. Tailored educational measures are
needed to ensure research results are better integrated in daily practice.anchester University NHS Foundation Trust, Manchester, United
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http://doi.org/10.1016/j.waojou.2020.100441Keywords: Severe asthma, Biological drug, Belief, BehaviorINTRODUCTION anti-IL5 receptor antagonist. These pharmacologicSevere asthma has been defined as “asthma that
requires use of high-dose inhaled corticosteroids
(ICS) plus a long-acting beta2-agonist (LABA) or
leukotriene modifier/theophylline for the previous
year or systemic corticosteroids for 50% of the
previous year (GINA steps 4–5 therapy) to prevent
it from becoming uncontrolled, or that remains
uncontrolled despite this therapy”.1 It affects 5–
10% of the total asthma population and imposes
a significant burden on health care due to high
rates of exacerbations and hospitalization.1
Mortality is a critical issue for these patients, and
it is more strongly associated with comorbidities
rather than asthma itself.2 Severe asthma is
associated with poor quality of life, reduced work
capacity, and social isolation.1
For many years maintenance systemic gluco-
corticoid treatment was the only option for pa-
tients with severe asthma. However, this therapy is
associated with many well-known side effects
including Cushing syndrome, adrenal insuffi-
ciency, osteoporosis, cataracts, glaucoma, high
blood pressure, and diabetes.3 Omalizumab, an
anti-IgE antibody was introduced in the early
2000s4 it was found to have glucocorticoid-sparing
benefits and a significant reduction in asthma
exacerbation rate.5 Although the adverse event
profile was comparable to placebo in the original
randomized controlled trials,4,5 a recent long-
term analysis revealed that omalizumab may be
associated with infections, musculoskeletal prob-
lems, angioedema, and hormonal disturbances.6 A
real-world analysis of a Japanese population
showed that the prevalence of side effects may be
as high as 30%; however, no placebo has been
included.7 Despite contradictory findings on the
predictive role of pre-treatment serum IgE
levels,8 omalizumab had clear benefit only in
allergic asthmatic patients. Recently, novel
treatments targeting the IL5 pathway have been
introduced. Mepolizumab9–11 and reslizumab are
monoclonal anti-IL5 antibodies that block IL5 in
the peripheral blood whereas benralizumab is anstrategies target eosinophilic airway inflammation;
however, they differ in their mode of administra-
tion, pharmacodynamic/pharmacokinetic proper-
ties, and mechanisms of action. Head-to-head
comparisons between anti-IL5 targeted biologics
are not available, and data from meta-analyses is
not conclusive, making it difficult to select one
therapy over another in the management of mod-
erate to severe eosinophilic asthma patients.12,13
Investigating side effects in clinical trials, the
most common adverse reactions include
nasopharyingitis, headache, and infections, the
most serious being anaphylactic reactions.14
Moreover, allergic and eosinophilic inflammation
commonly co-exist in severe asthma patients,
further complicating clinical decisions for selecting
an IL5 biologic versus an anti-IgE agent in these
patients.15 Interestingly, recent meta-analyses
showed no difference in the efficacy of omalizu-
mab versus anti-IL5 agents13,16 in patients with
overlapping phenotypes. Furthermore, the
biologic agents provide gains in quality-adjusted
survival over standard of care alone; however, the
benefit seems to be modeled over a lifetime span
at commonly accepted cost-effectiveness thresh-
olds based on a lower than the current market
price.17 Although historical studies are available
on real-life prescription pattern of omalizumab,18
these originate from the era before anti-IL5 treat-
ment. Since there is considerable overlap between
the indication of the 2 groups of drugs (ie, eosin-
ophilia vs. allergy), the current study aimed to re-
view prescribers’ choice in real-world settings. The
ultimate decision may depend on the physician’s
specialty training, their previous experience with
the management of severe asthma patients, and
the use of advanced therapies such as biologics.19
For all of these reasons, and because there is a gap
in knowledge providing clear guidance on the use
of novel biologics in moderate to severe asthma
patients, the choice by clinicians for a specific
biological strategy is still largely arbitrary. The
purpose of this study was to design and
distribute a questionnaire survey in order to
Male, No. (%) 156 (57,7)
Age, yrs, mean (SD) 47.7 (7.3)
Pulmonologists, No. (%) 130 (45.6)
Allergists, No. (%) 84 (29.5)
Internal medicine specialists, No. (%) 52 (18.2)
Paediatricians, No. (%) 19 (6.7)
Table 1. Demographic characteristics and specialty of the respondents (n ¼ 285)
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attitudes of primary care physicians, allergists/
clinical immunologists, and pulmonologists for the
treatment of severe asthma. We hypothesized that
specialty and previous experience with biologic
treatments (ie, omalizumab) would be significant
factors influencing the selection of an anti-IgE
versus an anti-IL5/anti-IL5R specific biologic. Anti
IL4/IL13 was not considered since it was not on the
market at the time of the survey.METHODS
The development of the questionnaire related
to prescribing attitudes involved 10 experts (3
pulmonologists, 3 allergists, 2 internal medicine
specialists, and 2 pediatricians) who were asked to
generate a list of single or multiple-choice ques-
tions in English. Applying a two-rounds Delphi
method,20 the experts were asked to rate on two
11-point Likert scales (from 0 ¼ disagree, to
10 ¼ agree) whether they believed each item
should be included in the final questionnaire and
the degree of agreement with the formulation of
the item. In the first round, experts were invited
to propose new formulations of items and to
suggest new items. Items with median relevance
score 6 were excluded, as were redundant
items, and 5 items were rephrased and were
added. In the second Delphi round, experts were
asked to re-rate their agreement for each item
included in the new list. Items with a relevance
score 7 were included in the electronic survey. It
(appendix 1) was composed 35 items divided into
4 sections: 1) Demography and previous use of
biological drugs for severe asthma (Q1-Q7); 2)
Behavior and beliefs about clinical issues related
to biological treatments (Q8-Q21), 3) Behavior andbeliefs about treatment schedules (Q22-Q28), and
4) Behavior and Beliefs about efficacy evaluation
(Q29-Q35).
The survey was circulated within the INESNET
network (109 members, mass email from the
headquarters), Interasma membership (>500
members, mass email from headquarters), contact
list of the co-authors, and social media (Facebook,
Twitter and LinkedIn) between June and
September 2018, and it was evaluated by the co-
authors. The invitation email contained an
encouragement to spread the survey in the mem-
bership social network. The outreach, especially on
social media, has not been quantified.
Statistical analyses
IBM SPSS 23 was used for statistical analysis.
Descriptive statistics were used for most of the
questions. In addition, we compared answers
provided by pulmonologists and allergists as well
as physicians with previous experience with only
Omalizumab (OMA) vs. those with experience of
Omalizumab plus anti-IL5 molecule (OMA/IL5) us-
ing chi-square tests. For the latter, a p value < 0.05
was considered significant.
RESULTS
Demography and use of biological drugs for
severe asthma
Out of 302 questionnaires completed, 285 were
suitable for analysis. All respondents referred to
prescribers of biological drugs for severe asthma.
Their demographic characteristics and specialty
(Q3) are reported in Table 1.
Prescribers from 37 countries participated in the
survey, 77% of them were from Europe; 44% were
Fig. 1 The prevalence of the responders in each country
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middle-income countries, and 8% from lower
middle (Q1-2, Fig. 1). In 37.2% of countries,
omalizumab was the only available biological
treatment for asthma, whereas in 40.7% of
countries, both omalizumab and mepolizumab
were available. In the remaining 22.1%,
benralizumab or reslizumab were available in
addition to omalizumab (Q4). 67.4% of physicians
had prescribed only omalizumab, while the
remaining respondents prescribed omalizumab
plus at least one other anti-IL5 biological drug
(23.9% mepolizumab, 8.7% other) (Q5-6). 75.4% of
the physicians declared that they had bureaucratic
limitations in prescribing biological drugs (Q7).
71.2% of prescribers tended to use biological
drugs instead of oral glucocorticoids in addition to
high doses of ICS/LABA, while 22.8% prescribed
biologics for patients on oral glucocorticoids with
the aim of tapering their dosage down (Q8).Behaviors and beliefs about clinical issues related
to biological treatments
54% of responders believed that the efficacy of
oral glucocorticoids predicts the efficacy of theavailable biological drugs, while 22% disagreed
with this opinion, and 24% had not formed an
opinion (Q9). 72% of physicians believed that the
efficacy of biological drugs exceeds their potential
side effects (Q10), 74% felt that they are safer than
long term treatment with 5 mg of prednisone
(Q11), and 52% considered that the potential
adverse events are less than 3 short-term bursts of
prednisone (Q12). 69% of participants stated that
in a patient with severe asthma, sensitization to
perennial allergens, and blood eosinophil >300/
mm3, omalizumab would be their first choice
(Q13). With respect to the ability to correctly
identify disease severity, less than 50% of re-
spondents were able to correctly classify the
severity according to the ATS/ERS criteria1 (Q14-
15; Fig. 2). Allergic status was considered by the
participants as the first clinical parameter on
which they would base their therapeutic
decisions (69.1%), followed by blood eosinophils
(24.9%) and sputum eosinophils (6%) (Q16).
72.2% of respondents considered >300/mm3
blood eosinophils significant while 10.1% aimed
for blood eosinophils >150/mm3 and 17.5%
aimed >400/mm3. 52.6% considered significant
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Q14. How do you consider a paent, on long term
treatment with high dose of ICS/LABA, presenng 1
exacerbaon in the previous year ( requiring 3 days of
OCS) and a FEV1 75% predicted?
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Fig. 2 ICS/LABA ¼ Inhaled corticosteroid/Long acting beta 2 agonist; OCS ¼ oral corticosteroid; FEV1 ¼ Forced expiratory; Volume in 1 s;
ACQ ¼ Asthma control questionnaire; ACT ¼ Asthma control test
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38.5% considered that to be >2% and 4%,
respectively (Q17-18).
Considering all the available biological drugs,
51% of physicians believed that omalizumab and
the anti-IL5 drugs are potential disease modi-
fiers; 18% and 19% responded that omalizumab
and mepolizumab are the most effective in such
cases (Q19). 43% of respondents were aware that
IL5 and IL5R receptors have different pharmaco-
logical effects, while 38% did not have an opinion
(Q20). 53% of participants could not decide
which biological drug is faster in ameliorating the
clinical status of their patients. Of the remaining,
9.8%, 12.6%, 3.2%, and 21.1% considered ben-
ralizumab, mepolizumab, reslizumab, and oma-
lizumab, respectively, as responding the fastest
(Q21).
Behavior and beliefs about treatment schedules
75% of prescribers considered the selection of a
specific route of administration as part of the
personalization of the patient’s treatment plan
(Q22-Q26, Table 3) 33% of participants believed
that anti IL5 molecules can reduce IgE, while 54%
that omalizumab is able to reduce eosinophils;
those without an opinion on the above topics
were 43% and 16%, respectively (Q27,28).
Behavior and beliefs about efficacy evaluation
30% of participants believed that none of the
available biologics are effective in inducing a
prompt relief of an asthma attack, while 35% ofrespondents had no opinion on this topic (Q29).
Responses to Q30 and Q31 are summarized in
Table 2.
Exacerbation rate at 6 months was considered
the most important clinical parameter in the
assessment of the efficacy of a biological treat-
ment (54%), followed by tapering/stopping of oral
steroids (33%) (Q32); 74 out of 285 participants
considered exacerbation rate in the following 6
months, tapering/stopping of oral steroid, and
ACT or ACQ score the most significant combina-
tion of parameters’ in evaluating the efficacy of a
biological treatment (Q33). Six months of treat-
ment was considered to be sufficient for judging
the efficacy by 53% of physicians, while 26%
preferred 3 months, 19% 12 months, and 2% 9
months (Q34).
34.4% of the sample had no opinion about the
most effective drug in treating concomitant nasal
polyposis, while 9.5% indicated benralizumab,
25.6% mepolizumab, 23.5% omalizumab, 5.3%
reslizumab as the best choice in such patients
(Q35).
Comparison of responses provided by allergists
and pulmonologists
Responses were compared from pulmonolo-
gists (n ¼ 130) and allergists (n ¼ 84). Data were
also compared from those with dual pulmonology
and allergology specialties (n ¼ 48), as well as
other specialties (n ¼ 23). A significant difference
between allergists and pulmonologists was
observed for 4 items. More pulmonologists (42%)
Question Answers Frequency Rate
Q30. What is your preferred therapeutic option in a severe
allergic asthma patient with an incomplete response to
Anti-IgE and blood Eos150?
To add an Anti IL-5
drug
80 28.1%
To switch to an anti
IL5
111 38.9%
Neither of the above 28 9.8%
I have not yet formed
an opinion
66 23.2%
Q31. What is your preferred therapeutic option in a severe
allergic asthma with an incomplete clinical response to anti-
IL5 and Eos 150
To add an Anti IgE
drug
113 39.6%
To switch to another
Anti IL5
54 18.9%
Neither of the above 26 9.1%
I have not yet formed
an opinion
92 32.3%
Table 2. Frequency and rate of answers to Q30 and Q31 Legend: Eos ¼ Eosinophil; IL5 ¼ interleukine 5, IgE ¼ Immunoglobulin E.
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opinion on which is the most effective biologic for
relieving an asthma attack (c2 ¼ 12.413;
p ¼ 0.030). Regarding responses for incomplete
clinical response to anti-IL5 in patients with severe
allergic asthma and blood eosinophils >150, more
allergists than pulmonologists tended to switch to
another anti-IL5 molecule, while 37% of pulmo-
nologists and 42% of allergists would have transi-
tioned to an anti-IgE antagonist (c2 ¼ 11.769;
p ¼ 0.008). More allergists (65%) than pulmonol-
ogists (47%) considered asthma exacerbation rate,
while more pulmonologists (42%) than allergists
(24%) considered tapering or stopping of oral
glucocorticoids as the most important clinical
parameter for assessing the efficacy of a biologic
(c2 ¼ 8.351; p ¼ 0.039). More pulmonologists
(41%) than allergists (21%) had not yet formed an
opinion (c2 ¼ 25.888; p ¼ 0.0001) regarding which
biologic was most effective for treating asthma
with concomitant nasal polyposis.
Comparison of responses from prescribers with
only previous omalizumab (OMA) experience vs
those with omalizumab and anti-IL-5 biologic
(OMA/IL5) experience
Among the 275 physicians who had experience
with omalizumab, 83 also had experience withanti-IL5 biologics while 192 did not. There were 14
significant differences between these two groups.
The OMA/IL5 respondents were less convinced
of the predictive effect of oral glucocorticoid effi-
cacy (50% vs 64%), while among OMA re-
spondents there was a higher response rate of
those who had not yet formed an opinion (26% vs
9%) (c2 ¼ 7.358; p ¼ 0.001). OMA/IL5 respondents
tended to be more confident that the efficacy of
biological drugs was greater than their potential
side effects (86.5% vs 69.7); the number of re-
spondents that had not formed an opinion on this
topic was lower among the OMA/IL5 group (4% vs
12%) (c2 ¼ 7.749; p ¼ 0.021). Similarly, OMA/IL5
were more confident that the potential adverse
events of biological drugs were less than those of
using long-term daily prednisone treatment with
prednisone compared to the OMA respondent
group (88% vs 69%) (c2 ¼ 9.343; p ¼ 0.009). OMA
respondents were more inclined to consider
allergic status as the most important biologic
parameter for considering treatment with a bio-
logic in severe asthma patients than OMA/IL5 (76%
vs 61%), who considered blood eosinophils as the
most important parameter (39% vs 18%)
(c2 ¼ 7.749; p ¼ 0.021).
Indication Mechanismof action
Route of
administration
Treatment
schedule
Tailored vs.
predefined
dose
Omalizumab For patients 6 years of
age and older with
moderate to severe
persistent asthma
who have a positive
skin test or in vitro
reactivity to a
perennial
aeroallergen and
whose symptoms are
inadequately
controlled with
inhaled
corticosteroids
anti-IgE Subcutenous Biweekly Tailored
Mepolizumab For 12 years
patients add on
maintance treatment
for patients with
severe asthma with
eosinophila (>150/mL)
anti-IL5 Subcutenous Monthly Predefined
Benralizumab For 12 years
patients add on
maintance treatment
for patients with
severe asthma with
eosinophila (>150/mL)
anti-IL5Ra Subcutenous Monthly for 3
months then
bimonthly
Predefined
Reslizumab For 18 years
patients add on
maintance treatment
for patients with
severe asthma with
eosinophila (>400/mL)
anti-IL5 Intravenous Monthly Tailored
Remark from
the survey
36.5%
considered
intravenous
and
subcutaneous
route equally
effective, while
23.5%
preferred
subcutaneous
and 9.8%
intravenous,
30% did not
have an
opinion on the
topic
66% preferred
monthly
administration,
7% bi-weekly;
27% bi-monthly
administration.
72% believed
that patients
prefer monthly,
and 22% a
bimonthly
regime
54% preferred a
tailored dose,
21% a
predefined
dose, and 11%
considered
these two
approaches
equal while 14%
had not formed
an opinion
Table 3. Comparison of indication, mechanism of action, route of administration and treatment schedule of the four investigated agents.
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consider allergic status as the first biological
parameter, while OMA/IL5 preferred blood EOS
count (c2 ¼ 13.007; p ¼ 0.001).
The percentage of OMA/IL5 respondents aware
that targeting IL5 or IL5R results in different phar-
macologic effects was greater than OMA re-
spondents (54% vs 37%), whereas a greater
number of OMA respondents had not formed an
opinion (44% vs 23%) (c2 ¼ 7.749; p ¼ 0.021).
Fewer OMA/IL5 (41%) respondents compared
to OMA (61%) respondents had not formed an
opinion about which biologic was faster in
improving clinical status (c2 ¼ 22.822 p ¼ 0.0001).
57% of OMA/IL5 and 29% OMA respondents
believed that intravenous and subcutaneous
routes of administration are equally effective, and
about 25% of both populations had not formed an
opinion on this topic. While OMA/IL5 respondents
preferred a tailored dose, OMA respondents
preferred a predefined dose, although 20% did
not have an opinion on this topic (c2 ¼ 14.635;
p ¼ 0.002).
Bimonthly administration was both the physi-
cians' and (in the physicians’ opinion would be the)
patient’s preferred schedule of treatment interval
for OMA/IL5 (42% and 51%) respondents, while
monthly administration was preferred among
OMA respondents (75% and 73%) (c2 ¼ 17.570;
p ¼ 0.0001).
More than 40% of OMA and OMA/IL5 re-
spondents did not have an opinion on the ability of
anti-IL5 drugs to reduce total IgE, although among
physicians who had already used anti-IL5 drugs,
36% were not confident, and 18% were confident
that these drugs worked in part through this
mechanism of action (c2 ¼ 8.985; p ¼ 0.011).
More OMA/IL5 than OMA respondents believed
that none of the available biologics were able to
promptly relieve asthma attacks; however, among
OMA/IL5 respondents, benralizumab and mepoli-
zumab were considered relievers and among the
OMA respondents, omalizumab was considered to
achieve this goal (c2 ¼ 27.240; p ¼ 0.0001).
The preferred therapeutic option in case of
incomplete clinical response to an anti-IL5 biologic
in a severe allergic asthmatic patient with morethan 150/mm3 peripheral eosinophils was to
switch or add an anti-IgE drug in 34% of OMA and
57% of OMA/IL5 respondents, respectively, and to
switch to another anti-IL5 molecule in 19% of OMA
and 18% of OMA/IL5 respondents, respectively
(c2 ¼ 12.921; p ¼ 0.005).
36% of OMA and 29% of OMA/IL5 respondents
had yet to form an opinion about the most effec-
tive drug in treating concomitant nasal polyposis,
while anti-IL5 molecules were preferred among
OMA/IL5 and omalizumab among the OMA re-
spondents (c2 ¼ 24.057; p ¼ 0.0001).DISCUSSION
Although some biological medications have
now been approved for the treatment of severe
asthma, there are still some uncertainties and in-
consistencies regarding their usage. More impor-
tantly, there is no guideline available as to whether
omalizumab or anti-IL5/anti IL5R drugs are the best
choices in patients who may qualify based on
phenotypic characteristics for both medications.
To date, there have not been any head-to-head
comparison studies conducted between bi-
ologicals, and meta-analyses have not shown sig-
nificant differences between drugs.13,15 Therefore,
it would be of interest to explore the prescribers’
beliefs and behavior in order to identify if
consolidated habits are reflected in research
results and to detect areas of uncertainty that
need to be the object of future research.
According to our knowledge, this is the first
study that has surveyed a large number of
prescribers regarding their attitudes and
approach to using biologics in asthma. In fact,
the survey covered 37 countries, though the
majority (almost three quarters) of respondents
were European. Therefore, other results can be
generalized mostly on the European and, to a
lesser extent, for American practice. Prescribers
are confident that the efficacy of available
biological drugs exceeds their potential side
effects and the adverse events of a long-term
treatment with a low dose of oral glucocorticoid.
It seems that further research is needed to
evaluate the comparative safety of 3 short-terms
burst of oral glucocorticoid/year versus biologics
as well their value as disease modifiers. Relevant
clinical issues such as differential time-related
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amelioration of clinical status as well as key pa-
rameters, the threshold useful for selecting the
treatment and their efficacy needs to be further
investigated. It is extremely surprising that about
50% of prescribers fail to adhere to the ATS/ERS
definition of severe asthma.1 In particular,
identifying “severe asthmatics” patients, those
with worse clinical features than those indicated
by international guidelines. This behavior likely
limits the use of biological treatments,
decreasing the individual and social benefits of
these treatments.
We found significant differences between aller-
gists and pulmonologists and more importantly
between those with and without anti-IL5 experience.
More pulmonologists (42%) than allergists (26%)
were uncertain of the most effective drug in the case
of an asthma attack; more allergists (38%) than pul-
monologists (28%) thought that these drugs are
equally effective. Interestingly, more allergists than
pulmonologists tended to switch to another anti-IL5
drug following an incomplete response to an anti-
IL5 treatment, behavior supported by the limited
available data.21 A key difference between
specialists was the identification of the best
therapeutic outcome, as allergists considered
exacerbation rate, while pulmonologists aimed at
tapering or stopping oral steroids. Both have been
represented as primary outcomes in clinical
trials.22–25 A possible reason for the differences
between pulmonologists and allergists could be
that pulmonologists are more confident in treating
asthma attacks and more concerned with the
possible long-term side effects of systemic gluco-
corticoids. Similarly, a more confident approach on
the treatment of concomitant nasal polyposis by al-
lergists might be due to their broader experience
with this disease.
As expected, significant differences have been
observed for 16 responses between omalizumab
prescribers who had previous experience with anti-
IL5 drugs compared to those who did not. OMA/
IL5 users were more confident in answering
questions regarding the potential benefit of bi-
ologics over their side effects. Most importantly,
when assessing a patient, prescribers without anti-
IL5 experience preferred assessing the allergic
status, which is an indication for the omalizumab
but not anti-IL5 treatment. As there is no head-to-head comparison study between the two types of
drugs in such a scenario, we have to assume that
many practitioners would choose omalizumab as a
first-line therapy due to the longer experience with
omalizumab. Not surprisingly, specialists with
previous experience with anti-IL5 drugs were
aware of the potential differences between the
anti-IL5 and anti-IL5R drugs. It is known that by
blocking IL5R, benralizumab induces natural killer
cell-dependent apoptosis of eosinophils.26
Although theoretically this may result in a greater
therapeutic effect, a recent meta-analysis failed to
prove the superiority of benralizumab over
mepolizumab or reslizumab.12 In fact, those who
had experience with anti-IL5 therapy did not
think that any of the anti-IL5 medications were
superior to the others, but they preferred a more
precision-based approach for each patient.27,28
More interestingly, doctors with previous anti-IL5
experience did not believe that switching to
another anti-IL5 following an incomplete response
to anti-IL5 treatment would be beneficial, despite
some conflicting evidence.15 Those with previous
anti-IL5 experience were confident that anti-IL5
drugs can be beneficial in concomitant nasal pol-
yposis and, in fact, a recent review concluded that
omalizumab, mepolizumab, and reslizumab are
effective in improving nasal polyposis.29 Previous
experience in using different biologics seems to
have a greater impact than specialty.
The study has some limitations. Although the
survey has been advertised by the Intersama and a
professional network (INESNET) as well as social
media, the outreach has not been quantified which
could limit the interpretation and generalization of
the data. Secondly, in 37% of the countries only
omalizumab was available, therefore the results of
the first part of the survey are influenced by the
lack of experience with anti-IL-5 agents. There may
be bureaucratic and financial limitations in drug
prescription, especially in that more than half of
the prescribers were from middle-income coun-
tries. A quarter of the prescribers mentioned
bureaucratic limitations when prescribing a bio-
logic treatment; however, financial limitations,
especially if the drug is fully or partially reimbursed
by the insurance, has not been analyzed. Many
prescribers believed that the potential side effects
of omalizumab and anti-IL5 agents are more
favorable than that of oral corticosteroids.
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http://doi.org/10.1016/j.waojou.2020.100441However, the anti-IL5 drugs were relatively very
new at the conduction of the survey, especially in
the middle-income countries, and prescribers may
not have come across late-onset side effects. This
uncertainty must be considered when evaluating
the data.INTERASMA SCIENTIFIC NETWORK
SUGGESTIONS RESULTING FROM
SURVEY’S RESULTS
The findings of this survey would be valuable for
policy makers and drug companies and may
facilitate improved implementation practices and
studies to answer the questions identified. Inter-
asma Scientific Network derived the following
suggestions from the above-mentioned results:
 Although a large majority of prescribers of bio-
logical drugs for asthma treatment are aware
that they must be used instead of oral steroids,
every effort should be made to further increase
awareness and to spread this information to all
physicians involved in asthma care.
 While a substantial majority of prescribers
believe that the available biological drugs are
safer than low dose long-term treatment with
oral steroids, a much lower percentage are
convinced of their safety in comparison with
short high-dose bursts of OCS. Further investi-
gation and educational campaigns are needed.
 The accuracy of prescribers to correctly identify
asthma severity according to the ATS/ERS
criteria is quite poor, limiting the use of effective
molecules in a significant percentage of patients.
Every effort should be made to improve physi-
cians' skills.
 Daily practice in the use of biological treatments
seems to suggest a disease modifier effect of
biological drugs. Further research is needed to
increase available knowledge.
 Uncertainty exists concerning the cut-off value of
available biomarkers for selecting responsive
patients, the outcomes to be evaluated for
assessing the efficacy of biological drugs, and
the timing of checks. These issues need to be
addressed by further research.Declaration of Competing Interest
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